Day: ខែ​កញ្ញា 25, 2025

Santa Clara, Münster, September 23rd, Tokyo 24th 2025, - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501, "Hitachi") is advancing the realization of a “Harmonized Society” where environment, wellbeing, and economic growth coexist in balance. As One Hitachi, the company is strengthening its portfolio to harness domain expertise and accelerate AI-driven innovations that transform social infrastructure. The Hitachi Group has agreed to acquire synvert, a company headquartered in Germany, as a wholly owned subsidiary of its U.S. subsidiary GlobalLogic Inc. (“GlobalLogic”)from Maxburg, a leading private equity fund focusing on founder-led technology companies inthe German-speaking region. This acquisition aims to accelerate the deployment of HMAX, Hitachi’s solution suite advancing operational autonomy and business model innovation through Agentic and Physical AI, solving customer and societal challenges in the AI era.synvert is a leading consulting firm in the data and......

TOKYO, Sept 25, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Electric Building Solutions Corporation (MEBS, Head Office: Chiyoda-Ku, Tokyo; President: Iwao Oda) today announced the introduction of KEGMIL, a cloud-based platform developed by the Singapore-based startup FTV LABS PTE. LTD. (FTV LABS) to improve the management of field services for elevator and escalator maintenance in overseas markets. KEGMIL will be launched in Singapore in October 2025, with the aim of expanding its deployment primarily across Southeast Asia and eventually to other regions.In today’s world, maintenance services for elevators and escalators have become increasingly important as a means of ensuring user safety and meeting the growing demands for convenience and comfort. At the same time, workforce aging and inefficient work processes are emerging as major issues. Introducing KEGMIL into elevator maintenance field services will allow MEBS to improve efficiency by allowing everything from work instructions and progre......

TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA)of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers.In response to February 2025 TGA decision not to approve lecanemab as a treatment for people with early AD, in March 2025, Eisai requested a review by the Administrative Review Tribunal. As a result of discussions during this process, the TGA and Eisai reached an agreement that led to the appr......